期刊文献+

促红细胞生成素联用氯沙坦治疗慢性心力衰竭 被引量:2

Treatment with erythropoietin and losartan in patients with chronic heart failure
下载PDF
导出
摘要 目的评价在慢性充血性心衰标准治疗的基础上加用促红细胞生成素和氯沙坦的临床疗效。方法入选的106例患者随机分为治疗组和对照组。治疗组(促红细胞生成素联用氯沙坦组)53例,对照组(常规治疗组)53例,进行对照分析。结果①治疗组治疗前后贫血指标及心功能指标的改善均优于对照组(P<0.05);②治疗组治疗前后生活质量评分及运动耐量的改善均优于对照组(P<0.05);③治疗组治疗后再住院率显著低于对照组(P<0.01);④两组治疗后未见明显不良反应。结论促红细胞生成素联用氯沙坦治疗慢性心力衰竭安全有效,心功能指标、贫血指标及运动耐力提高,减少了总住院时间,改善了生活质量。 Objective To assess the effects of erythropoietin (EPO) and losartan in patients with chronic heart failure (CHF). Methods 106 patients with CHF (NYHA class Ⅱ-Ⅳ) were randomly divided into 2 groups.53 in treatment grouop were treated by standard CHF medications plus EPO and losartan,53 in control group received standard CHF medications.Results There were significant increase in cardic function,Hb levels,exercise capacity,quality of life and 6 minutes walk distance in EPO group (P<0.05),but they were no significant changes in control group(P>0.05),and the rates of rehospitalization were obvious reduced in treatment group(P<0.01).Conclusion Treatment with EPO and losartan might improve the cardic function,exercise capacity,life quality and reduce the rates of rehospitalization of the patients with cardiac failure.
出处 《中国实用医药》 2007年第25期11-13,共3页 China Practical Medicine
关键词 慢性心力衰竭 贫血 促红细胞生成素 氯沙坦 运动耐量 Chronic heart failure Anemia Erythropoietin Losartan Exercise capacity
  • 相关文献

参考文献1

共引文献15

同被引文献25

  • 1中华医学会心血管病学分会 中华心血管病杂志编辑委员会.慢性心力衰竭诊断治疗建议.中华心血管病杂志,2007,35(12):1076-1095. 被引量:31
  • 2DEPPING R, KAWAKAMI K, OCKER H, et al. Expression of the erythropoietin receptor in human heart[ J]. J Thorac Cardiovasc Surg, 2005, 130(3) : 877 -878. 被引量:1
  • 3HIRATA A, MINAMINO T, ASANUMA H, et al. Erythropoietin enhances neovascularization of ischemic myocardium and improves left ventricular dysfunction after myocardial infarction in dogs [ J ]. J Am Coll Cardiol, 2006, 48(1) : 176 -184. 被引量:1
  • 4PRUNIER F, PFISTER O, HADRI L, et al. Delayed erythropoietin therapy reduces post - MI cardiac remodeling only at a dose that mobilizes endothelial progenitor cells[ J]. Am J Physiol Heart Circ Physiol, 2007, 292 ( 1 ) : H522 - 529. 被引量:1
  • 5WESTENBRINK B D, LIPSIC E, VAN DER MEER P, et al. Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization[J]. Eur Heart J, 2007, 28(16): 2018-2027. 被引量:1
  • 6WESTENBRINK B D, OESEBURG H, KLEIJN L, et al. Erythropoietin stimulates normal endothelial progenitor cell - mediated endothelial turnover, but attributes to neovascularization only in the presence of local ischemia[J]. Cardiovasc Drugs Ther, 2008, 22 (4) : 265 - 274. 被引量:1
  • 7WERNER N, KOSIOL S, SCHIEGEL T, et al. Circulating endothelial progenitor cells and cardiovascular outcomes [ J ]. N Eng J Med, 2005, 353(10): 999-1007. 被引量:1
  • 8ZENTILIN L, TAFURO S, ZACCHIGNA S, et al. Bone marrow mononuclear cells are recruited to the sites of VEGF - induced neovascularization but are not incorporated into the newly formed vessels[J]. Blood, 2006, 107(9) : 3546 -3554. 被引量:1
  • 9de BOER R A, PINTO Y M, van VELDHUISEN D J, et al. The imbalance between oxygen demand and supply as a potential mechanism in the pathophysiology of heart failure : the role of microvascular growth and abnormalities[ J]. Microcirculation, 2003, 10 (2) : 113 -126. 被引量:1
  • 10CHONG Z Z, KANG J Q, MAIESE K. Erythropoietin is a novel vascular protectant through activation of Aktl and mitochondrial modulation of cysteine proteases [ J ]. Circulation, 2002, 106 (23) : 2973 - 2979. 被引量:1

引证文献2

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部